A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 2, 2004, Pages 301-307

  Kase, S ^a   Osaki, Mitsuhiko ^a,b   Honjo, S ^a   Takeda, A ^a   Adachi, K ^a   Araki, K ^a   Ito, H ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Graduate School of Medicine   (Japan)

Author keywords

Cyclin B; Cyclooxygenase 2; Esophageal carcinoma; G2 M arrest; NS398

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; APOPTOTIC INDEX; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN TE 1; CELL STRAIN TE 12; CELL VIABILITY; DRUG EFFECT; ESOPHAGUS CARCINOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL DIVISION; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL NEOPLASMS; G2 PHASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MEMBRANE PROTEINS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 3242738451     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kargman S., Charleson S., Cartwright M., et al.: Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445-454, 1996.
2. Kujubu D.A., Reddy S.T., Fletcher B.S., Herschman H.R.: Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J. Biol. Chem. 268:5425-5430, 1993.
3. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A.: Expression of cyclooxygenase-2 in human Lung carcinoma. Cancer Res. 15:4997-5001, 1998.
4. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N.: Up-reguration of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994.
5. Kargman S.L., O'Neil G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S.: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:2556-2559, 1995.
6. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J.: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60:5767-577, 2000.
7. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schrör K.: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:198-204, 1999.
8. Kase S., Osaki M., Honjo S., et al.: Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 442:129-135, 2003.
9. Dempke W., Rie C., Grothey A., Schmoll H.J.: Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127:411-417, 2001.
10. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8:289-293, 2002.
11. Lahenvilie O., Breuer D.K., Dewitt D.L., Hla T., Funk C.D., Smith W.L.: Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271:927-934, 1994.
12. Smith W.L., Dewitt D.L.: Prostaglandin endoperoxide H synthase-1 and -2. Adv. Immunol. 62:167-215, 1996.
13. Taketo M.M.: Cyclooxygenase-2 inhibitors in tumorigenesis (Part 1). J. Natl. Cancer. Inst. 90:1529-1536, 1998a.
14. Taketo M.M.: Cyclooxygenase-2 inhibitors in tumorigenesis (Part 2). J. Natl. Cancer Inst. 90:1609-1620, 1998b.
15. Warner T.D., Giuliano F., Vojinovic I., Bukasa A., Mitchell J.A., Vane J.R.: Nonsteroid drug selectivities for cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96:7563-7568, 1999.
16. Zetterberg A., Larsson O., Wiman K.G.: What is the restriction point? Curr. Opin. Cell Biol. 7:835-842, 1995.
17. Nurse P.: Ordering S phase and M phase in the cell cycle. Cell 79:547-550, 1994.
18. Elder D.J., Halton D.E., Hague A., Paraskeva C.: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3:1679-1683, 1997.
19. Qadri S.S., Wang J.H., Redmond K.C., O'Donnell A.F., Aherne T., Redmond H.P.: The role of COX-2 inhibitors in lung-cancer. Ann. Thorac. Surg. 74:1648-1652, 2002.
20. Liu X.H., Yao S., Kirschenbaum A., Levine A.C.: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:4245-4249, 1998.
21. Toyoshima T., Kamijo R., Takizawa K., Sumitani K., Ito D., Nagumo M.: Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br. J. Cancer 86:1150-1156, 2002.
22. Li M., Wu X., Xu X.C.: Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway in esophageal cancer cells. Int. J. Cancer 93:218-223, 2001.
23. Schottenfeld D.: Epidemiology of cancer of esophagus. Semin. Oncol. 11:92-100, 1984.
24. Sarbia M., Verreet P., Bittinger F., et al.: Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 79:1871-1878, 1997.
25. Cheng J., Imanishi H., Amuro Y., Hada T.: NS-398, a selective cyclooxygenase-2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer 99:755-761, 2002.
26. Nishihira T., Hashimoto Y., Katayama M., Mori S., Kuroki T.: Molecular and cellular features of esophageal cancer cells. J. Cancer Res. Clin. Oncol. 119:441-449, 1993.
27. Tatebe S., Osaki M., Goto A., Ito H.: Taxol induces apoptosis in human colon carcinoma cell lines arrested in G2/M phase. Oncol. Rep. 4:1151-1156, 1997.
28. Gorczyca W., Gong J., Ardelt B., Traganous F., Darzynkiewicz Z.: The cell cycle related differences in susceptibility-of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:3186-3192, 1993.
29. Moreno S., Hayles J., Nurse P.: Regulation of p34cdc2 protein kinase during mitosis. Cell 58:361-372, 1989.
30. Nurse P.: Universal control mechanism regulating onset of M-phase. Nature 344:503-508, 1990.
31. Krek W., Nigg E.A.: Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transition of the cell cycle: identification of major phosphorylation sites. EMBO J. 10:305-316, 1991.
32. McGowan C.H., Russell P.: Human Wee 1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr 15. EMBO J. 12:75-85, 1995.
33. Gautier J., Solomon M.J., Booher R.N., Bazan J.F., Kirschner M.W.: Cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67:197-211, 1991.
34. Polyak K., Kato J.Y., Solomon M.J., et al.: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22, 1994.
35. Poon R.Y., Toyoshima H., Hunter T.: Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested With lovastatin or ultraviolet irradiation. Mol. Biol. Cell 6:1197-1213, 1995.
36. Reichert T.E., Nagashima S., Kashii Y., et al.: Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 19:514-525, 2002.
37. Huang Y.C., Chuang L.Y., Hung W.C.: Mechanisms underlying nonsteroidal anti-inflammatory drug-induced p27(Kip1) expression. Mol. Pharmacol. 62:1515-1521, 2002.